Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-08-27 | New | $275,000 | $275,000 | Equity Only | 06b | SEC link |
| 2021-07-28 | Amended | $1,498,325 | Unknown | Equity Only | SEC link | |
| 2021-07-21 | Amended | $983,325 | Unknown | Equity Only | SEC link | |
| 2021-05-26 | New | $150,000 | $150,000 | Equity Only | 06b | SEC link |
| 2021-05-11 | Amended | $1,650,000 | $1,600,000 | Equity Only | 06b | SEC link |
| 2021-04-30 | New | $50,000 | $50,000 | Equity Only | 06b | SEC link |
| 2020-09-23 | Amended | $570,000 | $70,000 | Equity Only | 06b | SEC link |
| 2020-08-12 | New | $500,000 | $500,000 | Equity Only | 06b | SEC link |
| 2020-01-15 | New | $100,000 | $100,000 | Equity Only | 06b | SEC link |
| 2019-12-13 | New | $75,000 | $75,000 | Equity Only | 06b | SEC link |
| 2018-11-27 | New | $40,000 | $40,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| John Abeles | Director |
| Nick Glover | Executive |
| Nicholas Glover | Director |
| Hans Keirstead | Director |
| Hans Kierstead | Director |
| Mark Frans Van Coeverden De Groot | Director, Executive |
| Andrew Williams | Executive |